secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001104659-23-113281
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annovis Bio prices $7.5M public offering of common stock and warrants
---------------------------------------------------------------------

- Offering of 1.25M units at $6.00/unit, each unit = 1 share + 1 warrant to buy 1 share at $9.00.
- Gross proceeds of ~$7.5M; net proceeds to fund clinical trials of buntanetap and general corporate purposes.
- Estimated cash and cash equivalents of $6.355M as of Sep 30, 2023 (unaudited, preliminary).
- Closing expected on or about Nov 2, 2023; Canaccord Genuity sole bookrunner.
- Warrants redeemable at $0.001 upon certain positive clinical data and stock price conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923113281/0001104659-23-113281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465923113281/tm2329368d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-113281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer